cagrilintide and semaglutide 2.4 mg Efficacy safety of co-administered once-weekly 2·4 with once-weekly 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial CagriSema guide 2026: FDA approval,

they may arise secondarily due to hypoglycemia (low blood sugar level), dehydration, gastrointestinal side effects, and interaction of semaglutide with other medications

This holistic approach is what leads to sustainable results that last long after the initial treatment phase

These figures are striking on both sides, but they come from two different trials with different lengths and patient populations and were never measured against each other so they describe each drug individually, not a winner

GLP-1 medications may support weight loss and metabolic health by helping regulate appetite, blood sugar response, and how quickly the stomach empties